Updated: FDA clears first CD20xCD3 bispecific, giving Genentech leg up in a crowded lymphoma R&D field
The first CD20xCD3 bispecific antibody will soon become available in the US following an FDA approval disclosed Thursday night, Dec. 22.
Roche and Genentech’s mosunetuzumab was greenlit as a third-line treatment for adults with relapsed or refractory follicular lymphoma. FDA’s accelerated approval of the therapy now branded as Lunsumio comes seven days early and follows suit behind the European Union, which cleared the drug on June 3, 2022.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters